The t(12;21)(p13;q22) translocation generates the TEL-AML1 (TEL, translocation-Ets-leukemia; AML1, acute myeloid leukemia-1) (ETV6-RUNX1) fusion product and is the most common chromosomal abnormality in pediatric leukemia. Our previous studies using a murine fetal liver transplantation model demonstrated that TEL-AML1 promotes the self-renewal of B-cell precursors in vitro and enhances the expansion of hematopoietic stem cells (HSCs) in vivo. This is consistent with the hypothesis that TEL-AML1 induces expansion of a preleukemic clone. Several studies have described domains within TEL-AML1 involved in the transcriptional regulation of specific target genes. However, it is unclear which of these domains is important for the activity of TEL-AML1 in preleukemic hematopoiesis. In order to examine this, we have generated a panel of deletion mutants and expressed them in HSCs. These experiments demonstrate that TEL-AML1 requires multiple domains from both TEL and AML1 to alter hematopoiesis. Furthermore, mutation of a single amino-acid residue within the runt homology domain of AML1, required for DNA binding, was sufficient to abrogate TEL-AML1 activity. These data suggest that TEL-AML1 acts as an aberrant transcription factor to perturb multiple pathways during hematopoiesis.
Introduction
The t(12;21)(p13;q22) translocation gives rise to the TEL-AML1 (TEL, translocation-Ets-leukemia; AML1, acute myeloid leukemia-1) gene fusion and is the most common chromosomal abnormality yet identified in any pediatric leukemia (Golub et al., 1995) . This translocation results in fusion of part of the TEL gene, encoding the N-terminal non-DNA binding region of this erythroblast transformation-specific (ETS)-family member, to almost the entire AML1 gene (Romana et al., 1995; Shurtleff et al., 1995) . TEL (also known as ETV6) and AML1 (also known as RUNX1) are frequent targets of other chromosomal translocations in human leukemias, and inactivation of either gene disrupts normal hematopoietic development (Okuda et al., 1996; Wang et al., 1996 Wang et al., , 1997 Wang et al., , 1998 . TEL-AML1 is a chimeric transcription factor that can bind AML1 target sequences and potentially deregulate gene expression in cells harboring the translocation. TEL-AML1 has been shown to inhibit AML1-dependent transcription of several promoters in transient transfection assays and functional domains of both TEL and AML1 are required for this activity Fears et al., 1997; Fenrick et al., 1999; Uchida et al., 1999) . These studies suggested that the TEL moiety of the fusion converts AML1 from an activator to a repressor of transcription. A similar mechanism has been proposed for the activity of another AML1 fusion, AML1-ETO, which results from the t(8;21) translocation in AML (Meyers et al., 1995) . However, alternative mechanisms of TEL-AML1 activity have also been suggested. TEL-AML1 may sequester transcriptional cofactors into a cytoplasmic non-functional complex which would indirectly interfere with AML1 function (Rho et al., 2002) . In addition, TEL-AML1 has also been shown to disrupt the activity of wild-type TEL, by dimerization via the helix-loop-helix (HLH) domains (McLean et al., 1996; Gunji et al., 2004) . The mechanism of TEL-AML1 activity in leukemia may thus be complex, using multiple pathways to alter the transcription of endogenous genes.
Several studies have led to the hypothesis that the TEL-AML1 gene fusion is the initiating event in t(12;21) leukemogenesis, generating a preleukemic clone that requires secondary mutations to produce overt leukemia (Wiemels et al., 1999; Mori et al., 2002; Greaves et al., 2003) . Furthermore, expression of the TEL-AML1 fusion protein is insufficient to directly induce leukemia in mouse models (Andreasson et al., 2001; Bernardin et al., 2002; Morrow et al., 2004) . Three recent studies using retroviral transduction of primary murine progenitors have shown that TEL-AML1 alters normal hematopoiesis in a manner consistent with preleukemic activity. Thus, we demonstrated that TEL-AML1 enhanced the self-renewal capacity of B-cell progenitors in colony-forming assays in vitro and conferred a competitive advantage on hematopoietic reconstitution in vivo (Morrow et al., 2004) . Other studies observed an accumulation of early B-cell progenitors expressing TEL-AML1 (Tsuzuki et al., 2004; Fischer et al., 2005) . To understand further the mechanism of TEL-AML1 action, we have analysed the activity of TEL-AML1 deletion mutants in vitro and in vivo. We demonstrate a requirement for multiple functional domains of TEL-AML1, from both the TEL and AML1 portions, for lineage-specific expansion of hematopoietic stem cells (HSC). Our data support the hypothesis that TEL-AML1 is involved in multiple transcriptional pathways and that this activity is a critical priming event in t(12;21) leukemogenesis.
Results

Expression of domain deletion mutants of TEL-AML1 using retroviral vectors
To determine which domains are required for TEL-AML1 activity in vitro and in vivo, we generated a number of deletion mutants based on previous studies (Fenrick et al., 1999; Uchida et al., 1999; Guidez et al., 2000) (Figure 1 ). These studies found that deletion of the runt homology domain (RHD) domain abolished TEL-AML1 binding to AML1 consensus sequences, whereas deletions of the C-terminal transactivation domain of AML1 or the HLH domain of TEL did not affect the ability of TEL-AML1 to bind to DNA (Uchida et al., 1999) . The complementary DNAs (cDNAs) were inserted into the murine stem cell virus (MSCV)-based retroviral vector pMSCV-IRES-EGFP upstream of the internal ribosome entry site (IRES) and a cDNA encoding enhanced green fluorescent protein (EGFP). The mutant constructs included a deletion of the HLH domain of TEL (MSCV-DHLH), a deletion of the central repression (CR) domain and sequences downstream of the HLH domain of TEL (MSCV-DCR), a deletion of the RHD of AML1 (MSCV-DRHD), and two C-terminal truncations of AML1 deleting the transactivation domain, repression domain and VWRPY motif of AML1 (MSCV-D214 and MSCV-D289). An MSCV vector expressing full length AML1 cDNA (MSCV-AML1) was also generated. In addition, a construct containing a point mutation within the RHD of TEL-AML1 was generated (MSCV-R201Q). R201Q is the most frequent mutation in the RHD of AML1 in human patients, found in familial platelet disorder with predisposition to AML (Song et al., 1999) , AML (Preudhomme et al., 2000) and cleidocranial dysplasia (Quack et al., 1999; Zhou et al., 1999; Otto et al., 2002; Yoshida et al., 2002) . Conservative mutation of this amino acid, at the corresponding position in mouse AML1 (R174), reduces the affinity of the AML1 RHD domain for DNA by 1000-fold, without disrupting heterodimerization with the corebinding factor (CBF)b cofactor or perturbing the RHD fold (Li et al., 2003) .
Mouse c-Kit
þ fetal liver cells purified from embryonic day 12 (E12) C57BL/6 fetal liver were transduced with the deletion mutant vectors, MSCV-T/A or MSCV-EGFP empty vector. Expression of the appropriate size mutant TEL-AML1 protein in 3T3 cells was confirmed by Western blot analysis using anti-HA antibodies (Figure 2a) . A doublet is detected for all constructs containing the N terminus of TEL owing to the M43 alternative TEL translational start site (Poirel et al., 1998) . This was confirmed by Western blot analysis of TEL-AML1 constructs mutated to delete one or other of the translational start sites (data not shown). Retroviral transduction of primary c-Kit þ cells was confirmed based on EGFP expression (Figure 2b ).
DNA binding of the mutant TEL-AML1 protein panel was examined by electrophoretic mobility shift assay (EMSA). In this assay, TEL-AML1 shows only weak DNA binding, the binding being more readily visualized upon supershifting of the complex using an anti-HA monoclonal antibody (mAb) (Figure 3 ). In agreement with previous studies Uchida et al., 1999) , full length AML1 and the D214, D289 and DHLH mutants, all showed enhanced DNA binding in comparison with TEL-AML1, Figure 1 TEL-AML1 deletion mutant constructs. Depicted are the wild-type TEL and AML1 proteins, the TEL-AML1 fusion protein and various mutant TEL-AML1 proteins that lack the HLH or CR domains of TEL, the RHD of AML1, two deletions of the transactivation domain and C-terminal amino acids of AML1, or contain an RHD point mutation. Numbers represent amino-acid residues of wild-type TEL or AML1. All constructs were tagged with an HA epitope as indicated. Overexpression of AML1 inhibits B-cell development in vitro As the TEL-AML1 fusion protein retains virtually the entire AML1 protein, it has been suggested that some of the effects of TEL-AML1 on hematopoiesis may simply be the result of deregulated AML1 expression (Cameron and Neil, 2004) . In order to determine whether the TEL moiety of the fusion is required to promote B-cell differentiation in vitro, we included a construct expressing full length AML1 in the experiments above. Upon retroviral transduction of cells with MSCV-AML1, we consistently observed a lower percentage of EGFP expression post-transduction ( Figure 2b ). After the first round of plating, the number of colonies and cells generated by MSCV-AML1 cultures was greatly reduced, compared to MSCV-EGFP cultures ( and d) and cells surviving in the MSCV-AML1 cultures were largely EGFP-negative untransduced cells. These data suggest that overexpression of AML1 is not permissive for B-cell differentiation in these cultures. This effect is probably specific to hematopoietic cells, as AML1-transduced 3T3 cells maintained constant EGFP expression during culture over a 10-day period (data not shown).
An RHD mutation disrupting DNA binding abrogates TEL-AML1 activity Although the RHD deletion has previously been shown to abrogate DNA binding of TEL-AML1 (Uchida et al., 1999) , this domain is also responsible for binding CBFb, the non-DNA-binding heterodimerization partner of AML1 (Scandura et al., 2002) . In order to determine which function of the RHD is required for TEL-AML1 activity, the colony forming ability of c-Kit þ cells transduced with the MSCV-R201Q construct was analysed. Expression of the appropriate size mutant TEL-AML1 protein in 3T3 cells was confirmed by Western blot (Figure 5a ) and retroviral transduction of c-Kit þ cells was confirmed by EGFP expression (Figure 5b ). The number of colonies and B220 þ cells generated by the MSCV-R201Q methylcellulose cultures was much lower than that produced by the MSCV-T/A cultures and similar to the MSCV-EGFP controls (Figure 5c-e) . In addition, the MSCV-R201Q cells only generated colonies for three rounds of plating. This suggests that the DNA binding function of the RHD is essential for TEL-AML1 activity.
The C-terminal domain of AML1 is not required for immortalization of pre-B cells Colonies harvested from tertiary cultures were pooled and cells were placed in liquid culture containing IL-7, SCF and FLT3L. Under these conditions, only MSCV-T/A, MSCV-D214 and MSCV-D289 cultures gave rise to growth factor-dependent immortalized cell lines. We established three lines, from three independent experiments, for each deletion mutant and full-length TEL-AML1. These cell lines were continually maintained in liquid culture for over 3 months (data not shown). The growth factor requirements of the MSCV-D214 and MSCV-D289 cell lines were comparable to MSCV-T/A Figure S2b in Supplementary Information). Expression of EGFP and cell-surface markers by the cell lines was equivalent to that of cells harvested from the third round of methylcellulose culture. These data suggest that the C-terminal domains of AML1 are not required for in vitro immortalization of pre-B cells by TEL-AML1.
The C terminus of AML1 is required for the full effect of TEL-AML1 in vivo We next analysed the effect of the D214 and D289 TEL-AML1 mutants on hematopoietic reconstitution in vivo, in order to establish whether the domains deleted were completely dispensable for TEL-AML1 activity. Donor c-Kit þ cells from C57BL/6-Ly5.2 mice were transduced with low, but equivalent, titers of MSCV-D214, MSCV-D289, MSCV-T/A or MSCV-EGFP viruses such that only a fraction of the cells were infected (16-25% of cells, Figure 6 ). These cells were then transplanted into sublethally irradiated C57BL/6-Ly5.1 mice. Six weeks We also consistently noted a trend for more efficient repopulation by MSCV-D289-transduced cells (3.34% 72.29) compared to MSCV-EGFP-infected cells, although this was not statistically significant (P ¼ 0.077). However, neither the D214 nor the D289 mutant promoted reconstitution to the extent of full-length TEL-AML1 (13.74% 72.98, P ¼ 0.00015, compared to empty vector cells).
Reconstitution of specific hematopoietic lineages by MSCV-D214 or MSCV-D289 transduced cells was then examined. As expected, EGFP þ cells were clearly enriched in mice transplanted with MSCV-T/Atransduced cells compared to mice transplanted with MSCV-EGFP-transduced cells in the myeloid (Mac1 þ ) (Figure 6b ) and B-cell (B220 þ ) lineages (Figure 6c ) (Po0.02 for B and myeloid lineages). We observed a smaller, but significant, increase in repopulation of the B and myeloid lineages of peripheral blood in mice transplanted with MSCV-D214-transduced cells (4.75%72.12 and 1.28% 70.65, respectively) compared Three months post-transplantation, the mice were killed and the contribution of the transduced HSCs to the bone marrow and spleen was analysed. We observed a similar effect of the deletion mutants in these organs as with peripheral blood (data not shown). A further experiment was performed, using lethally irradiated recipients and a larger number of mice per group, to confirm that although the D214 and D289 mutants promoted hematopoietic reconstitution more efficiently than the empty vector, they were significantly less active than TEL-AML1 in this assay (Figure 7 ). This data suggests that although both domain mutants of TEL-AML1 can induce expansion of HSC in vivo, they are less efficient than full length TEL-AML1.
Discussion
We have generated deletion mutants of TEL-AML1 in order to determine which domains are required for activity of this fusion in our established model of the t(12;21) translocation (Morrow et al., 2004) . In this model we have previously shown that TEL-AML1 affects hematopoiesis in two different ways. In vitro, TEL-AML1 promoted B-cell differentiation but not myeloid development. In contrast, TEL-AML1-expressing HSC showed a competitive advantage in reconstituting both B-cell and myeloid lineages in vivo. In the present study, our data demonstrate that the HLH and CR domains of TEL, and the RHD domain of AML1 are all required for the promotion of in vitro B-cell differentiation by TEL-AML1. Furthermore, the ability of the RHD to bind DNA is required for this activity. In contrast, loss of the C-terminal domains of AML1, D214 and D289, did not alter TEL-AML1 activity in this assay. However, these domains were required to mediate the full effect of TEL-AML1 on hematopoietic reconstitution in vivo. As hematopoietic reconstitution is likely to be a more stringent test of TEL-AML1 activity, it is possible that it reveals a function of the AML1 Cterminal domains not obvious in the in vitro B-cell differentiation assay.
Our data demonstrate that the HLH domain of TEL is required for TEL-AML1 activity in HSC and that the DHLH mutant inhibits B-cell differentiation in vitro. Interestingly, the inhibition is similar to that observed when overexpressing AML1. Previous studies have shown that the HLH domain is required for the transcriptional repression of AML1-dependent promoters by TEL-AML1 Fears et al., 1997; Fenrick et al., 1999; Uchida et al., 1999) . TEL-AML1 lacking a HLH domain activates AML1-dependent transcription, albeit not as effectively as AML1. Although the HLH domain is required for oligomerization of TEL-AML1, it contributes to repression primarily by recruiting the mSin3A transcriptional corepressor (Fenrick et al., 1999) . In addition to 
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inhibiting AML1-dependent transcriptional activation, TEL-AML1 has also been shown to interfere with transcriptional repression by wild-type TEL (Gunji et al., 2004) . This activity of TEL-AML1 is dependent on association between the fusion protein and wild-type TEL, an interaction mediated by the HLH domain. Interestingly, loss of TEL function is thought to cooperate with TEL-AML1 in leukemogenesis, as the untranslocated TEL allele is frequently deleted in t(12:21)-associated leukemias (Romana et al., 1995; Kim et al., 1996; Raynaud et al., 1996) . These studies suggest that the HLH domain is necessary for inhibition of both AML1 and TEL transcriptional activity by TEL-AML1. It is possible that both of these functions of TEL-AML1 are required for the promotion of B-cell development from HSC in our experiments. Transcriptional repression has also been ascribed to the CR domain, a central region of TEL retained in the TEL-AML1 fusion (Lopez et al., 1999) . This region has been shown to recruit the corepressor N-CoR and histone deacetylase-3 (Guidez et al., 2000; Wang and Hiebert, 2001) . We found that the region of TEL Cterminal of the HLH domain, which includes the CR domain, is also essential for TEL-AML1 to initiate progenitor B-cell expansion from HSC. The requirement of both the HLH and CR domains of TEL suggests that the transcriptional repressor function, conferred on TEL-AML1 by the TEL moiety, is critical to activity of this fusion in HSC.
Our data demonstrate that the RHD domain of AML1 is also required for TEL-AML1 activity in the in vitro assays. A deletion of the RHD domain identical to the one used in our study has been shown to abolish binding of TEL-AML1 to AML1 target sequences (Uchida et al., 1999) . However, the RHD domain is also responsible for binding CBFb, the non-DNA-binding heterodimerization partner of AML1, and transcription factors such as ETS proteins, Smads and CCAAT/enhancer binding proteina (Scandura et al., 2002) . In order to establish whether the DNA binding function of the RHD domain is important for TEL-AML1 function, we made a TEL-AML1 construct with a point mutation in the RHD which disrupts DNA but not CBFb binding. The R201Q mutation abrogated the ability of TEL-AML1 to enhance B-cell differentiation. These data indicate that DNA binding is essential to TEL-AML1 function in HSC and suggests that TEL-AML1 acts by directly interfering with AML1-dependent transcription rather than by simply sequestering co-activator molecules (Rho et al., 2002) .
Upon binding regulatory regions of target genes, AML1 has been suggested to facilitate the assembly of protein complexes involved in both transcriptional activation and repression, in a cell type-specific manner Durst and Hiebert, 2004) . Thus AML1 can either repress or activate the p21 WAF-1 promoter depending on cell type. The Cterminal part of AML1, downstream of the RHD domain, contains distinct regions involved in recruiting co-activators and corepressors of transcription. The region of AML1 lost in the D289 deletion mutant contains a transactivation domain, a nuclear matrix localization signal (NMTS) and a VWRPY motif. The transactivation domain has been shown to bind coactivators such as p300/CBP (Kitabayashi et al., 1998) and ALY (Bruhn et al., 1997) , and the NMTS domain localizes AML1 to transcriptionally active subnuclear domains (Zeng et al., 1997 (Zeng et al., , 1998 , whereas the VWRPY motif binds the Groucho/TLE corepressors (Aronson et al., 1997; Imai et al., 1998; Javed et al., 2000) . However, the D289 deletion mutant retains the region responsible for binding the mSin3 family of corepressors (Fenrick et al., 1999; Lutterbach et al., 2000) . 
Plots show the means and s.e., (n ¼ 10 for MSCV-EGFP and MSCV-D214, and n ¼ 9 for MSCV-T/A and MSCV-D289). The percentage of donor EGFP þ cells in MSCV-D214-and MSCV-D289-transplanted mice was significantly less than in MSCV-T/A-transplanted mice (Po0.001), and in MSCV-D289-transplanted mice was significantly greater than in MSCV-EGFP-transplanted mice (P ¼ 0.008).
A deletion mutant of TEL-AML1 almost identical to D289 retained the ability to repress AML1-mediated transactivation of the CR1 promoter (Rho et al., 2002) and IL-3 promoter activity (Uchida et al., 1999) . Interestingly, repression of the IL-3 promoter was lost upon further C-terminal truncation of TEL-AML1, up to amino-acid residue 216 of AML1 (Uchida et al., 1999) , possibly due to disruption of the mSin3 binding domain . These data suggested that the D214 and D289 TEL-AML1 mutants would have differential activity in our assays. We found no difference between the activity of either of these mutants and full-length TEL-AML1 in promoting B-cell development and immortalizing B-cell progenitors in vitro. It appears, therefore, that none of the TEL-AML1 domains C-terminal of the RHD domain are required for activity of this fusion in this assay. Alternatively, a requirement for the deleted domains in vitro may have been overcome by the enhanced DNA binding activity of both deletion mutants. However, although the D214 and D289 mutants did enhance hematopoietic reconstitution in vivo, they were less effective than full-length TEL-AML1. We did not observe a consistent difference between the two C-terminal mutants in vivo, despite consistently observing a large effect of TEL-AML1 on hematopoietic reconstitution. This suggests that the C-terminal regions of AML1 do have a role in TEL-AML1 function in vivo, which is not revealed by the in vitro assays, and may be important for promoting expansion of HSC leading to preleukemic clone formation.
Several studies have reported amplification and overexpression of the AML1 gene in childhood acute lymphoblastic leukemia (Niini et al., 2000; Busson-Le Coniat et al., 2001; Dal Cin et al., 2001; Mikhail et al., 2002) . TEL-AML1 retains virtually the full-length AML1 gene product and it has been suggested that this fusion may be functionally analogous to overexpression of normal AML1 (Cameron and Neil, 2004) . However, this does not appear to be the explanation for the effects of TEL-AML1 on in vitro B-cell development in our experiments, as AML1 overexpression inhibited B-cell growth and differentiation. AML1 is expressed in HSC and at all stages of B-cell development (Lorsbach et al., 2004) . Conditional knockout studies have demonstrated that AML1 is required for normal B-cell development (Ichikawa et al., 2004; Growney et al., 2005) . Our data suggest that overexpression of AML1 may also result in defective B-cell development. The sensitivity of hematopoietic cells to the levels of AML1 is well characterized and haploinsufficiency of AML1 results in decreased HSC activity but increased numbers of multilineage progenitors . It was suggested that this would result in an increased pool of progenitor cells in which the accumulation of further mutations may lead to leukemia. Indeed haploinsufficiency of AML1 and loss-of-function point mutations in AML1 have been both implicated in predisposition to myeloid leukemia (Osato et al., 1999; Song et al., 1999) . If TEL-AML1 interferes with AML1 activity it is likely that this would result in increased progenitor generation and predisposition to leukemia. However, it is probable that TEL-AML1 has other activities in addition to inhibition of AML1 function, as this fusion is not associated with myeloid leukemia.
In summary, we demonstrate a requirement for multiple functional domains of TEL-AML1, from both the TEL and AML1 portions, for lineage-specific expansion of HSC. Our data support the hypothesis that TEL-AML1 is involved in multiple transcriptional pathways and that this activity is a critical priming event in t(12;21) leukemogenesis.
Materials and methods
Mice
All mice were maintained in the animal facilities of the Institute of Child Health, London, and experiments were performed according to United Kingdom Home Office regulations and Institute of Child Health institutional guidelines.
Retroviral constructs and infection of hematopoietic progenitor cells
The pMSCV-IRES-EGFP (MSCV-EGFP) and pMSCV-TEL-AML1-IRES-EGFP (MSCV-T/A) vectors have been described previously (Morrow et al., 2004) . The deletion mutant cDNAs were cloned into the pMSCV-IRES-EGFP vector, upstream of the IRES-EGFP. To generate MSCV-DHLH and MSCV-DCR, the appropriate TEL sequences were amplified by polymerase chain reaction (PCR) using TEL-AML1 as a template and ligated in frame with the XbaI site of AML1. Primer sequences used in PCR reactions are shown in the Table in Supplementary Information. MSCV-DRHD was created by deleting the AvrII-Bsu36I fragment from the TEL-AML1 cDNA. MSCV-D214 and MSCV-D289 were generated by amplifying the truncated AML1 sequence of the construct by PCR and ligating it in frame to the XbaI site of TEL-AML1. This PCR reaction incorporated a hemagglutinin (HA)-epitope tag to allow detection of the mutant proteins by Western blotting. Fulllength AML1 was constructed by cloning synthetic oligonucleotides (sequences shown in the Table in Supplementary Information) of the first 57 bp of AML1 into the XbaI site of AML1 in place of the TEL portion of the fusion. The R201Q RHD point mutation was introduced into MSCV-TEL-AML1-IRES-EGFP using the Quikchange Multi Site-Directed Mutagenesis kit (Stratagene, Cambridge, UK) according to the manufacturer's instructions. All constructs were sequenced to ensure there were no PCR introduced errors. Production of retroviral supernatants and infection of progenitor cells have been described previously (Morrow et al., 2004) . Briefly, c-Kit þ cells were purified from embryonic day-12 (E12) fetal liver of C57BL/6 mice by magnetic-activated cell sorting using allophycocyanin (APC)-conjugated anti-c-Kit (2B8) mAb (eBioscience, San Diego, CA, USA), and anti-APC magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Cells were infected in the presence of 10 ng/ml fms-like tyrosine kinase-3 ligand (Flt-3L), 20 ng/ml interleukin-7 (IL-7) and 100 ng/ml SCF. All recombinant growth factors were of mouse origin (Peprotech EC, London, UK). Following retroviral infection, cells were used for colony-forming assays or in vivo reconstitution assays.
Domain analysis of TEL-AML1 M Morrow et al EMSA Nuclear lysates were prepared from transfected LinXE cells. Briefly, 1 Â 10 7 cells were washed twice with phosphatebuffered saline and incubated on ice for 5 min with hypotonic lysis buffer (20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulphonic acid (pH 7.6), 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.1% Triton X-100, 25 mM NaF, 25 mM b-glycerophosphate, 1 mM dithiothreitol (DTT), and protease inhibitors). Nuclei were then pelleted by centrifugation at 0.1 g for 5 min and resuspended in 200 ml of hypertonic buffer (hypotonic buffer plus 500 mM NaCl) and incubated at 41C for 1 h. The nuclear extracts were cleared of debris by centrifugation at 16 g for 5 min. The amount of transfected HA-tagged protein in the nuclear extracts was quantitated by Western blot using a GS-800 densitometer and Quantity One software (Bio-Rad, Hertfordshire, UK).
The AML1 binding site from the IL-3 promoter (Uchida et al, 1999) was created by annealing the complementary oligonucleotides 5 0 -CTAGGTCTGTGGTTTTCTAG-3 0 and 5 0 -CTAGCTAGAAAACCACAGAC-3 0 . Oligonucleotides (0.4 ng per reaction) were radiolabeled with [a-32 P] dCTP using Klenow enzyme and incubated with 10 mg nuclear extract at room temperature for 15 min in a buffer containing 12.5 mM NaCl, 2.5 mM Tris pH 7.4, 0.25 mM MgCl2, 0.25 mM EDTA, 0.25 mM DTT, 1.25% glycerol and 1 mg poly dI:dC (GE Healthcare Ltd, UK). Where indicated, 1 mg anti-HA antibody (clone 3F10; Roche Applied Science, Indianapolis, IN, USA) was added to the binding reaction to supershift the transfected HA-tagged protein. Specificity of DNA binding was confirmed by including 200 Â molar excess of unlabelled oligonucleotide in the binding reaction. This was sufficient to compete out binding of proteins to the radiolabelled oligonucleotide (data not shown). Following incubation, the samples were loaded onto a 5% polyacrylamide gel and run in 0.25 Â Tris-borate-EDTA.
Transplantation assays
Sublethally g-irradiated (5 Gy) recipient C57BL/6-Ly5.1 mice were injected intravenously with 2 Â 10 5 c-Kit þ cells (Ly5.2 þ ) 48 h after infection with retroviral supernatants. Reconstitution of hematopoietic lineages was determined by analysis of peripheral blood 6 weeks after transplantation. Mice were killed after 14 weeks for analysis of bone marrow and spleen. Statistical significance of differences between data obtained from mice transplanted with MSCV-EGFP-transduced cells compared to mice transplanted with MSCV-TEL-AML1-, MSCV-D214-or D289-transduced cells was determined using a two-tailed Student's t-test. For the experiment using lethally irradiated (9 Gy) mice, recipients were C57BL/6-Ly5.2 mice and donor c-Kit þ fetal liver cells were from F1 (C57BL/ 6-Ly5.1/Ly5.2) mice. Donor cells were distinguished from recipient cells by virtue of Ly5.2 and Ly5.1 coexpression.
Colony-forming assays and generation of pre-B-cell lines Colony forming assays were conducted as previously described (Morrow et al., 2004) . Briefly, transduced c-Kit þ fetal liver cells were cultured in 1.1-ml duplicate methylcellulose (Stem Cell Technologies, Vancouver, Canada) cultures (1 Â 10 4 cells/ plate) supplemented with 20 ng/ml IL-7, 10 ng/ml Flt3L, and 100 ng/ml SCF. Secondary and tertiary assays were performed by replating between 1 Â 10 3 and 1 Â 10 4 cells/plate, under identical conditions. Colonies were stained with 1 mg/ml p-iodonitrotetrazolium (INT) (Sigma-Aldrich, Poole, UK) in phosphate-buffered saline (PBS). To generate pre-B-cell lines in liquid culture, cells were pooled from tertiary assays.
Flow cytometry
Cells were stained with phycoerythrin-, APC-, or biotinconjugated mAb specific for c-Kit (2B8), B220 (RA3-6B2), BP-1 (6C3), Mac-1 (M1/70), Ly5.2 (104) and Ly5.1 (A20) (eBioscience) and CD19 (1D3), CD43 (S7) and isotope control antibodies (BD Pharmingen, San Diego, CA, USA). Cells were resuspended in PBS, 0.5% bovine serum albumin, and 0.05% sodium azide, and preincubated with unlabeled anti-FcgIII/II receptor mAb2.4G2 before staining with primary antibody. Biotin-conjugated mAbs were visualized using StreptavidinTricolour (Caltag, Burlingame, CA, USA) or StreptavidinPerCP (BD Pharmingen). Four-color cytometry was performed on a Cyan (DakoCytomation, Ely, UK) and data were analysed using Summit software (DakoCytomation).
Western blot analysis of protein expression Cell extracts were prepared using radioimmunoprecipitation assay buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris (tris(hydroxymethyl)aminomethane) pH8.0, 5 mM EDTA, 10 mg/ml aprotinin, 250 mg/ml phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 10 mg/ml pepstatin A). Protein samples were resolved on a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Immobilon-P; Millipore, Billerica, MA, USA). Membranes were blocked in PBS with 5% nonfat milk and 0.2% Tween-20, and then stained with anti-HA (clone 3F10; Roche Applied Science, Indianapolis, IN, USA), or anti-actin (clone I-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Proteins were detected by the appropriate secondary horseradish peroxidaseconjugated antibodies and a chemiluminescent reagent (ECL; GE Healthcare, Buckinghamshire, UK), according to the manufacturer's instructions.
